NASDAQ:IKT

Inhibikase Therapeutics (IKT) Stock Price, News & Analysis

Inhibikase Therapeutics logo
$1.30 +0.01 (+0.38%)
Closing price 11/20/2026 03:59 PM Eastern
Extended Trading
$1.30 0.00 (-0.31%)
As of 11/20/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Inhibikase Therapeutics Stock (NASDAQ:IKT)

Advanced

Key Stats

Today's Range
$1.28
▼
$1.37
50-Day Range
$1.30
▼
$2.39
52-Week Range
$1.28
▼
$2.61
Volume
1.11 million shs
Average Volume
577,338 shs
Market Capitalization
$183.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.75
Consensus Rating
Moderate Buy

Company Overview

Inhibikase Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for Parkinson’s disease and other neurodegenerative disorders. The company’s research centers on small-molecule inhibitors of Abelson tyrosine kinase, or c-Abl, a protein it is investigating for its role in neurodegeneration.

Its pipeline has included IKT-148009, an oral c-Abl inhibitor being developed for Parkinson’s disease. Inhibikase is based in Atlanta, Georgia, and conducts research and development in the pharmaceutical biotechnology sector.

AI Generated. May Contain Errors.

Inhibikase Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
50th Percentile Overall Score

IKT MarketRank™: 
2.502452010645 of 5 stars

Inhibikase Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 482nd out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Inhibikase Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 3 strong buy ratings, 4 buy ratings, 2 hold ratings, and 1 sell rating.

  • Upside Potential

    Inhibikase Therapeutics has a consensus price target of $4.75, representing about 264.0% upside from its current price of $1.31.

  • Amount of Analyst Coverage

    Inhibikase Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Inhibikase Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Inhibikase Therapeutics are expected to decrease in the coming year, from ($0.41) to ($0.44) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Inhibikase Therapeutics is -3.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Inhibikase Therapeutics is -3.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Inhibikase Therapeutics has a P/B Ratio of 0.97. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    14.99% of the float of Inhibikase Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Inhibikase Therapeutics has a short interest ratio ("days to cover") of 28.59, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Inhibikase Therapeutics has recently decreased by 1.01%, indicating that investor sentiment is improving.
  • Dividend Yield

    Inhibikase Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Inhibikase Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Inhibikase Therapeutics has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for Inhibikase Therapeutics this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    3 people have added Inhibikase Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Inhibikase Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    7.10% of the stock of Inhibikase Therapeutics is held by insiders.

  • Percentage Held by Institutions

    3.81% of the stock of Inhibikase Therapeutics is held by institutions.

  • Read more about Inhibikase Therapeutics' insider trading history.
Receive IKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IKT Stock News Headlines

IKT Stock Gets Increased EPS Forecast from HC Wainwright
Worse than socialism
Donald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.tc pixel
Inhibikase Therapeutics' (IKT) Buy Rating Reaffirmed at HC Wainwright
See More Headlines

IKT Stock Analysis - Frequently Asked Questions

Inhibikase Therapeutics' stock was trading at $2.05 at the start of the year. Since then, IKT stock has decreased by 36.3% and is now trading at $1.3050.

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) issued its quarterly earnings data on Tuesday, November, 10th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.01.

Inhibikase Therapeutics's stock reverse split on Friday, June 30th 2023.The 1-6 reverse split was announced on Friday, June 30th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

Inhibikase Therapeutics (IKT) raised $20 million in an initial public offering (IPO) on Wednesday, December 23rd 2020. The company issued 1,800,000 shares at a price of $10.00-$12.00 per share. ThinkEquity​ (a division of Fordham Financial Management) served as the underwriter for the IPO.

Top institutional investors of Inhibikase Therapeutics include Soleus Capital Management L.P. (8.00%), RA Capital Management L.P. (4.97%), State Street Corp (1.59%) and Nantahala Capital Management LLC (1.39%).
View institutional ownership trends
.

Shares of IKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Inhibikase Therapeutics investors own include Palantir Technologies (PLTR), Altria Group (MO), Energy Transfer (ET), Micron Technology (MU), Advanced Micro Devices (AMD), Intel (INTC) and ServiceNow (NOW).

Company Calendar

Last Earnings
11/10/2026
Today
11/22/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:IKT
Previous Symbol
NYSE:IKT
CIK
1750149
Fax
N/A
Employees
35
Year Founded
2008

Price Target and Rating

High Price Target
$8.00
Low Price Target
$1.50
Potential Upside/Downside
+264.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.40)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$48.26 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-40.53%
Return on Assets
-38.44%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
15.34
Quick Ratio
15.34

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.35 per share
Price / Book
0.97

Miscellaneous

Outstanding Shares
140,270,000
Free Float
130,311,000
Market Cap
$183.05 million
Optionable
N/A
Beta
0.94

Social Links

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (NASDAQ:IKT) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners